Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult beta-thalassemia major

Carla Casu, Roberta Chessa, Alison Liu, Ritama Gupta, Hal Drakesmith, Robert Fleming, Yelena Z. Ginzburg, Brian MacDonald, and Stefano Rivella

Disclosures: S.R. is a member of scientific advisory board of Ionis Pharmaceuticals. S.R. is consultant for Disc Medicine, Protagonist and La Jolla Pharmaceutical Company. Y.Z.G serves as a consultant for La Jolla Pharmaceutical Company and has received funding from ApoPharma. R.F. is on the Scientific Advisory Board of Protagonist Therapeutics. H.D. has received research funding from Pfizer. The remaining authors declare no competing financial interests. Acknowledgements: This work was supported by Merganser Biotech and grants from the National Institute of Diabetes and Digestive and Kidney Diseases and National Heart, Lung, and Blood Institute of the National Institutes of Health: R01 DK090554 (S.R.), R01 DK095112 (R.F., S.R., and Y.Z.G.), R01 DK107670 (Y.Z.G). CBC analysis (complete blood count) was performed by the Translational Core Lab of CHOP Research Institute and the Institutional Clinical and Translational Science Award Research Center, NIH/NCATS (National Center for Advancing Translational Sciences), Grant UL1TR000003.

Contributions: Contribution: C.C., R.C., A.L. and R.G. performed research and analyzed the results; S.R., Y.Z.G., R.F., B.M., H.D., C.C., R.C., A.L. and R.G. discussed the experiments, analyzed results, wrote and reviewed the paper.